Retatrutide 10mg
GLP-1 / GIP / Glucagon Triple Receptor Agonist | 10mg Lyophilised Powder
About Retatrutide 10mg
Retatrutide (LY3437943) is a novel triple incretin receptor agonist developed by Eli Lilly, targeting GLP-1R, GIPR, and glucagon receptors simultaneously. This triple-action mechanism distinguishes it from dual agonists like tirzepatide, offering researchers a unique tool for studying synergistic metabolic receptor activation. It represents the cutting edge of incretin biology and obesity/metabolic disease research.
Research Applications
- Triple incretin receptor (GLP-1R/GIPR/GcgR) activation and signalling studies
- Obesity and body weight regulation pathway modelling
- Insulin secretion, glucose homeostasis and beta-cell function assays
- Metabolic disease (T2DM, NAFLD) pathway research
- Cardiovascular risk factor and lipid metabolism studies
Technical Specifications
| Target Receptors | GLP-1R, GIPR, Glucagon R |
| Molecular Weight | ~4.8 kDa |
| Purity | ≥98% (HPLC verified) |
| Form | Lyophilised powder |
| Storage | -20°C, protected from light |
| Quantity | 10mg per vial |
Certificate of Analysis
All compounds supplied by Monumental Peptides are independently tested by a third-party laboratory using HPLC and Mass Spectrometry, with purity confirmed at ≥98%. Certificates of Analysis are available upon request — simply contact us after placing your order.
Request Certificate of Analysis →Related Research Compounds
Ready to Order Retatrutide 10mg?
UK stock · Fast dispatch · Full documentation included
Order Now — £44.99 →